Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291297 · ClinicalTrials.gov registry record · Phase 2
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
A Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Metastatic, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT07291297: Recruiting Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Metastatic, sponsored by Wake Forest University Health Sciences.
NCT07291297 is a Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Metastatic that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants, below the 73-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07291297, a Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Metastatic, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.
Primary Outcome
12-month overall survival (OS) will be determined for each participant as a binary variable indicating whether the participant was surviving at 12 months after study enrollment. Failure occurs if the participant dies from any cause within 12 months of study enrollment (initiation of metformin).
Conditions Studied
Interventions
- DRUG Metformin Hydrochloride ER
Study Locations (2)
North Carolina
- Levine Cancer Institute - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-03-04 |
| Est. Completion | 2033-10 |
| Phase | Phase 2 |
What NCT07291297 shows while recruiting
NCT07291297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 73-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with Sarcoma,Soft Tissue appearing as the primary indexed condition, and to 1 intervention - of which Metformin Hydrochloride ER is the first listed.
NCT07291297 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07291297 about?
NCT07291297 is a clinical study titled "Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma". The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.
What is the current status of trial NCT07291297?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-03-04. Estimated completion is 2033-10.
What conditions does trial NCT07291297 study?
This clinical trial studies the following conditions: Sarcoma,Soft Tissue, Sarcoma Metastatic.
What interventions are being tested in trial NCT07291297?
The interventions under investigation include: Metformin Hydrochloride ER (DRUG).
Who is sponsoring clinical trial NCT07291297?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07291297 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma,Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07291297's enrollment target sits among peer trials
50 6th of 12 higher than 7 of 12 other Sarcoma,Soft Tissue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma,Soft Tissue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI